39 heavily shorted Healthcare stocks rated Buy or better (Nov 2026)
39 heavily shorted Healthcare stocks rated Buy or better by the Lician Quant rating as of Nov 4, 2026, including Exelixis Inc (EXEL), DaVita HealthCare Partners Inc (DVA), Immunitybio Inc (IBRX). Short interest of 10% of float or more at the latest FINRA settlement, while the quant rating is Buy or Strong Buy: where short sellers and the factors disagree.
Open this screen in the full screener to add filters, sort by any factor and save it.
39 stocks · Strong Buy or Buy · Healthcare · Short ≥ 10% of float
| Stock | Quant ratingRating | ValuationVal | GrowthGrow | ProfitabilityProf | MomentumMom | EPS revisionsRev | Market capMkt cap | P/EP/E | Revenue growthRev YoY | Div. yieldYield | Short % floatShort | Next earningsEarnings |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1BCYCBicycle Therapeutics Ltd | 4.04Buy | B+ | A+ | D+ | D | A- | $257M | NM | +194.7% | — | 183.3% | — |
| 2MAZEMaze Therapeutics, Inc. Common Stock | 3.65Buy | D+ | — | C- | B | A- | $1.7B | NM | — | — | 78.2% | Nov 5 |
| 3QTTBQ32 Bio Inc | 5.00Strong Buy | A+ | — | A+ | B | A | $206M | 6.1 | — | — | 57.9% | Nov 12 |
| 4IBRXImmunitybio Inc | 3.52Buy | F | A+ | D | B- | A | $8.7B | NM | +192.9% | — | 31.2% | — |
| 5SGRYSurgery Partners Inc | 4.30Buy | A- | D+ | B | A- | B- | $3.0B | NM | +4.0% | — | 26.4% | Nov 9 |
| 6LQDALiquidia Technologies Inc | 4.15Buy | B | A+ | A+ | C | F | $3.8B | 27.4 | +2,234% | — | 26.1% | — |
| 7GRDNGuardian Pharmacy Services, Inc. | 4.73Strong Buy | A+ | — | B | C+ | B | $359M | 5.4 | +10.3% | — | 26.1% | Nov 5 |
| 8GRALGRAIL, LLC | 4.48Buy | D+ | A- | D+ | A | A+ | $5.6B | NM | +23.1% | — | 24.4% | Nov 4 |
| 9ARQTArcutis Biotherapeutics Inc | 4.92Strong Buy | C+ | A+ | A- | A- | B+ | $3.9B | 137.4 | +76.1% | — | 23.9% | Nov 4 |
| 10ANIPANI Pharmaceuticals Inc | 4.67Strong Buy | A+ | A | A | D | C+ | $1.6B | 14.8 | +30.9% | — | 22.7% | Nov 5 |
| 11CRMDCorMedix Inc | 4.14Buy | A+ | A+ | A+ | F | D- | $579M | 3.1 | — | — | 22.0% | Nov 11 |
| 12OMEROmeros Corporation | 4.86Strong Buy | C | — | — | A- | A+ | $1.2B | 9.6 | — | — | 20.4% | Nov 12 |
| 13RIGLRigel Pharmaceuticals Inc | 4.82Strong Buy | A+ | B+ | A+ | A | D- | $895M | 2.8 | +3.3% | — | 18.3% | Nov 5 |
| 14AGENAgenus Inc | 3.85Buy | B | B- | A+ | C+ | F | $291M | 3.2 | +30.5% | — | 18.1% | Nov 5 |
| 15MGTXMeiraGTx Holdings PLC | 4.82Strong Buy | A | A+ | A+ | D | B- | $897M | 11.4 | +948.3% | — | 17.6% | Nov 12 |
| 16INSPInspire Medical Systems Inc | 4.33Buy | A | B+ | A | C- | C- | $2.1B | 15.2 | +4.3% | — | 16.7% | — |
| 17ARDTArdent Health Partners, Inc. | 3.76Buy | A+ | D | B | C+ | C- | $1.7B | 21.2 | +3.3% | — | 15.4% | Nov 4 |
| 18IOVAIovance Biotherapeutics Inc | 3.64Buy | F | — | D | A | A+ | $6.4B | NM | +34.5% | — | 15.2% | Nov 5 |
| 19CDNACareDx Inc | 4.98Strong Buy | C+ | B+ | A+ | A+ | A+ | $3.6B | 32.2 | +34.4% | — | 13.6% | — |
| 20EXELExelixis Inc | 4.69Strong Buy | C+ | B | A+ | A+ | C- | $17.5B | 19.7 | +9.1% | — | 13.4% | — |
| 21LGNDLigand Pharmaceuticals Incorporated | 3.94Buy | D+ | C | A- | B+ | — | $6.1B | 118.8 | +1.0% | — | 13.3% | — |
| 22PDEXPro-Dex Inc | 4.79Strong Buy | A | A- | B+ | C+ | A- | $184M | 13.4 | +16.5% | — | 13.0% | — |
| 23DVADaVita HealthCare Partners Inc | 4.07Buy | A- | C+ | A- | C+ | C | $11.8B | 12.8 | +6.4% | — | 12.9% | — |
| 24BCRXBioCryst Pharmaceuticals Inc | 3.58Buy | D+ | A+ | C | C | B- | $2.1B | NM | +68.7% | — | 12.8% | Nov 4 |
| 25EVHEvolent Health Inc | 4.00Buy | B | B+ | D | B | B | $514M | NM | +139.6% | — | 12.6% | Nov 5 |
Source: Lician Quant Grades (SEC EDGAR statements, EODHD prices and estimates); short interest: FINRA; earnings dates: earnings calendar; dividend yield: EODHD fundamentals · Quant run Nov 4, 2026
Grades rank each stock against its sector peers; they are not investment advice. How the rating and grades work · Short interest · Earnings calendar
Heavily shorted, rated Buy in other sectors
About this screen
- Which are the top heavily shorted Healthcare stocks rated Buy or better?
- As of Nov 4, 2026, the highest ranked are Bicycle Therapeutics Ltd (BCYC, rating 4.04); Maze Therapeutics, Inc. Common Stock (MAZE, rating 3.65); Q32 Bio Inc (QTTB, rating 5.00); Immunitybio Inc (IBRX, rating 3.52); Surgery Partners Inc (SGRY, rating 4.30). 39 stocks pass the screen in total.
- What does this screen look for?
- Short interest of 10% of float or more at the latest FINRA settlement, while the quant rating is Buy or Strong Buy: where short sellers and the factors disagree.
- How is the Lician Quant rating calculated?
- Each stock gets five factor grades (Valuation, Growth, Profitability, Momentum, EPS Revisions) from A+ to F by ranking its metrics against the other stocks in its sector. The rating (1.00 to 5.00) is the equal-weight average of the factor scores, re-ranked within the sector: 4.50 and up is Strong Buy, 3.50 Buy, 2.50 Hold, 1.50 Sell, below that Strong Sell.
- How often is the list updated?
- After every US trading day, from SEC filings, EODHD prices and analyst estimates; this list is from the quant run of Nov 4, 2026. Short interest follows FINRA's twice-monthly settlement dates.